Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 16/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31031255 | 1.00 | ELANE (0.53) | ELANELMNAMAPTNPSR1MAPK1 | |
| SCHEMBL28370638 | 0.84 | ELANE (0.62) | ELANELMNAMAPTNPSR1 | |
| SCHEMBL10491994 | 0.83 | ELANE (0.34) | ELANEMAPK1 | |
| SCHEMBL29372709 | 0.83 | ELANE (0.34) | ELANEMAPK1 | |
| SCHEMBL44659 | 0.83 | ELANE (0.34) | ELANEMAPK1 | |
| SCHEMBL16868476 | 0.81 | ELANE (0.33) | ELANEMAPK1 | |
| SCHEMBL20306504 | 0.81 | ELANE (0.54) | ELANELMNAMAPTNPSR1MAPK1 | |
| SCHEMBL17938475 | 0.81 | ELANE (0.54) | ELANELMNAMAPTNPSR1MAPK1 | |
| SCHEMBL4887181 | 0.79 | ELANE (0.53) | ELANELMNAMAPTNPSR1MAPK1 | |
| SCHEMBL29607284 | 0.77 | ELANE (0.74) | ELANELMNAMAPTNPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116891425-A | Alpha-trifluoromethyl diazonium sulfonium salt compound and application thereof | 遵义医科大学 | 2023-10-17 | — | — | CN | claimed |
| US-20230159485-A1 | Methods for Preparing Cannabinoids and Related Instruments | 3BC, LLC (US) | 2023-05-25 | — | — | US | claimed |
| CN-110776442-A | Preparation method of memantine hydrochloride intermediate | 华中科技大学 | 2020-02-11 | — | — | CN | claimed |
| US-10543481-B2 | Targeted, metal-catalyzed fluorination of complex compounds with fluoride ion via decarboxylation | TRUSTEES OF PRINCETON UNIVESITY (US) | 2020-01-28 | — | — | US | claimed |
| EP-2755989-B1 | METHOD FOR PREPARATION OF BETULINIC ACID | STORA ENSO OYJ (FI) | 2018-01-31 | — | — | EP | claimed |
| EP-2755989-A1 | METHOD FOR PREPARATION OF BETULINIC ACID | Stora Enso Oyj (FI) | 2014-07-23 | — | — | EP | claimed |
| WO-2013038316-A1 | METHOD FOR PREPARATION OF BETULINIC ACID | STORA ENSO OYJ (FI) | 2013-03-21 | — | — | WO | claimed |
| US-20250092468-A1 | BIOMARKERS OF RESPONSE TO HIF-2-ALPHA INHIBITION IN CANCER AND METHODS FOR THE USE THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-03-20 | — | — | US | disclosed |
| US-12234516-B2 | Biomarkers of response to HIF-2-alpha inhibition in cancer and methods for the use thereof | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-02-25 | — | — | US | disclosed |
| US-12187702-B2 | Sulfonamideurea compounds | INFLAZOME LIMITED (IE) | 2025-01-07 | — | — | US | disclosed |
| US-12012392-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2024-06-18 | — | — | US | disclosed |
| US-RE49948-E1 | Aryl ethers and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2024-04-30 | — | — | US | disclosed |
| WO-2024058311-A1 | METHOD FOR PRODUCING ECTOINE | 김형식 | 2024-03-21 | — | — | WO | disclosed |
| US-20130116285-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-09 | — | — | US | disclosed |
| WO-2013038316-A1 | METHOD FOR PREPARATION OF BETULINIC ACID | STORA ENSO OYJ (FI) | 2013-03-21 | — | — | WO | disclosed |
| WO-2012007883-A1 | SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012007877-A2 | CHEMICAL COMPOUNDS | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012007861-A1 | N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
| US-20120010183-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
| US-20120010207-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10543481-B2 | Targeted, metal-catalyzed fluorination of complex compounds with fluoride ion via decarboxylation | AFF2, CLTC, AFF4 | ELANE 4014/4885LMNA 3051/4885MAPT 1505/4885 |
| US-20120010207-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | ELANE 2487/4885LMNA 2892/4885MAPT 3240/4885 |
| US-12187702-B2 | Sulfonamideurea compounds | NLRP3, NOD1, NLRP1 | ELANE 2474/4885LMNA 1367/4885MAPT 3064/4885 |
| US-20230159485-A1 | Methods for Preparing Cannabinoids and Related Instruments | CNR2, CNR1, FAAH | ELANE 544/4885LMNA 226/4885MAPT 3693/4885 |
| US-20120010183-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | ELANE 840/4885LMNA 2928/4885MAPT 4559/4885 |
| US-20130116285-A1 | Chemical Compounds | SCN1A, SCN10A, SCN1B | ELANE 1769/4885LMNA 2319/4885MAPT 3685/4885 |
| US-12234516-B2 | Biomarkers of response to HIF-2-alpha inhibition in cancer and methods for the use thereof | HIF1AN, HIF1A, EGLN2 | ELANE 2207/4885LMNA 3216/4885MAPT 4789/4885 |
| US-12012392-B2 | Sulfonamide carboxamide compounds | NLRP3, PYCARD, NOD1 | ELANE 1837/4885LMNA 1939/4885MAPT 2011/4885 |
| US-20250092468-A1 | BIOMARKERS OF RESPONSE TO HIF-2-ALPHA INHIBITION IN CANCER AND METHODS FOR THE USE THEREOF | HIF1AN, HIF1A, EGLN2 | ELANE 2207/4885LMNA 3216/4885MAPT 4789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.